Entering text into the input field will update the search result below

Gamida Cell: Recapping A Tough Year

Nov. 02, 2021 12:17 PM ETGamida Cell Ltd. (GMDA)6 Comments


  • Today, we revisit an intriguing Israeli-based biotech concern called Gamida Cell for the first time since March.
  • The shares have seen declines in 2021, like most small biotechs this year, even as the company continues to march to its first FDA approval.
  • Time to buy the dip? A full investment analysis follows in the paragraphs below.
  • Looking for a portfolio of ideas like this one? Members of The Biotech Forum get exclusive access to our model portfolio. Learn More »

Regenerative Medicine

wildpixel/iStock via Getty Images

Never lose hope. Storms make people stronger and never last forever.”― Roy T. Bennett

2021 had been a rough year so far for small developmental concern Gamida Cell (NASDAQ:GMDA), as it has been for

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE.

This article was written by

Bret Jensen profile picture

Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.

Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GMDA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (6)

Busted IPO Forum profile picture
The U.S. Food and Drug Administration (FDA) granted priority review to Gamida Cell's (NASDAQ:GMDA) application seeking approval of stem cell therapy omidubicel to treat patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.
The FDA accepted the company's Biologics License Application (BLA) and is expected to make a decision by Jan. 30, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review.
Gamida said the FDA is not planning to hold an Advisory Committee meeting as part of the BLA review.
The company noted that the BLA was backed by data from a phase 3 trial.
any further commentary on GMDA?
Tried looking for a catalyst. Do you (Brett) think they will need either a debt or stock offering to get the marketing going?
Bret Jensen profile picture
@t3536gj Hard to tell which route they will go. Based on burn rate, it looks likely at some point in 2022. If they get FDA approval, still should be up year for stock imho
Reading61 profile picture
@Bret Jensen Some good news. I think it might finally start to move up. Thanks. Gary
Bret Jensen profile picture
@Reading61 Crossing fingers. Best
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About GMDA

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on GMDA

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.